Cynapsus Therapeutics to Present at the BIOCOM Global Life Science Partnering Conference
Marketwire, February 18, 2022
TORONTO – Cynapsus Therapeutics Inc. (CTH: TSX-V) today announced that Anthony J. Giovinazzo, President and Chief Executive Officer, will present at the BIOCOM Global Life Science Partnering Conference at 4:45 P.M. PST, Wednesday, February 23rd, at the Estancia Hotel & Spa in La Jolla, California. Mr. Giovinazzo will provide an overview of the company and discuss its lead candidate, APL-130277, an improved dosage form of the approved drug, apomorphine, in development to treat symptoms of Parkinson’s disease.
About Cynapsus Therapeutics
Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus’ lead drug candidate, APL-130277, is a reformulation of an approved drug for the treatment of motor fluctuation in Parkinson’s disease. APL-130277 is designed to be a convenient, fast-acting rescue of patients experiencing motor fluctuations from “off” episodes during the day. The reformulation could address a much larger moderate to severe patient population than the current subcutaneous form, which represents approximately 25% to 50% of Parkinson’s patients. The company is focused on rapidly maximizing the value of APL-130277 by advancing it to pivotal studies in advance of a New Drug Application expected to be completed by the end of 2012, followed by out-licensing to an appropriate pharmaceutical partner. More information about Cynapsus (CTH: TSX-V) is available at www.cynapsus.ca.
Contact Information:
Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
[email protected]
Media contacts:
Russo Partners LLC
Derek Moates
(212)-845-4242
[email protected]
Robert E. Flamm, Ph.D.
(212)-845-4226
[email protected]
--30--
